<DOC>
	<DOCNO>NCT02431247</DOCNO>
	<brief_summary>The purpose study demonstrate non-inferiority efficacy darunavir/cobicistat/emtricitabine/tenofovir alafenamide ( D/C/F/TAF ) fix dose combination ( FDC ) tablet versus Darunavir/Cobicistat ( DRV/COBI ) FDC coadministered Emtricitabine/tenofovir disoproxil fumarate ( FTC/TDF ) FDC human immunodeficiency virus-1 ( HIV-1 ) infect , antiretroviral ( ARV ) treatment naive adult participant .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide ( D/C/F/TAF ) Fixed Dose Combination ( FDC ) Versus Regimen Consisting Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC Treatment-naive HIV Type 1 Infected Subjects</brief_title>
	<detailed_description>This Phase 3 , multicenter ( one hospital medical school team work medical research study ) , randomize ( study drug assign chance ) , double-blind ( medical research study neither researcher participant know treatment participant receiving ) , active-controlled ( study experimental treatment procedure compare standard [ control ] treatment procedure ) study . The study consist 5 period : Screening period , Double-blind treatment period , Single-arm treatment period , Extension period Follow-up period . Participants receive either darunavir ( DRV ) / cobicistat ( COBI ) /emtricitabine ( FTC ) /tenofovir alafenamide ( TAF ) fix dose combination ( D/C/F/TAF FDC ) DRV/COBI FDC along FTC/TDF FDC . Primarily percentage participant human immunodeficiency virus ( HIV ) -1 Ribonucleic acid ( RNA ) less ( &lt; ) 50 copy per milliliter ( copies/ml ) define snapshot analysis evaluate . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>Subject must antiretroviral ( ARV ) treatmentnaive ( never treat ARV include postexposure prophylaxis preexposure prophylaxis ) ; prior use approve experimental anti human immunodeficiency virus ( antiHIV ) drug length time Screening plasma HIV1 ribonucleic acid ( RNA ) level great equal &gt; =1,000 copy per milliliter ( copies/mL ) Cluster Differentiation 4+ ( CD4+ ) cell count &gt; 50 cells/microliter ( cells/mcL ) Screening HIV1 genotype report must show full sensitivity DRV , TDF FTC Screening eGFRcreatinine &gt; =70 mL/min accord CockcroftGault formula creatinine clearance Subject diagnose new acquired immunodeficiency syndrome ( AIDS ) define condition within 30 day prior screen Subject proven suspect acute hepatitis within 30 day prior screen Subject hepatitis C hepatitis B positive Subject history cirrhosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Immunodeficiency Virus Type 1 , Human</keyword>
	<keyword>Darunavir</keyword>
	<keyword>Cobicistat</keyword>
	<keyword>Tenofovir Alafenamide</keyword>
	<keyword>Emtricitabine</keyword>
	<keyword>Tenofovir Disoproxil Fumarate</keyword>
</DOC>